The research, led by Shimao Xiong, Naiyi Yin, and Yanshan Cui of the College of Resources and Environment at the University of Chinese Academy of Sciences, together with colleagues at Peking University People’s Hospital, set out to answer a deceptively simple question: does arsenic encountered before or shortly after birth program the gut microbial community in ways that persist or even amplify later in life? To find out, the team built a carefully staged exposure model in C57BL/6J mice, one of the most widely used strains in biomedical research. Pregnant females were given drinking water laced with arsenic at an environmentally relevant concentration of 0.10 milligrams per liter, with exposure beginning either on gestational day zero, before embryos had even implanted, or on gestational day fourteen, during late organogenesis. Exposure then continued through lactation, meaning that pups were dosed both in the womb and through their mother’s milk.

The consequences for growth were immediate and, crucially, dependent on when exposure began. Pups whose mothers started drinking arsenic-contaminated water on gestational day zero showed markedly reduced body weight at weaning, while pups exposed only from gestational day fourteen onward actually gained weight significantly faster than controls. That divergence is more than a curiosity. It implies that the earliest embryonic window, when the foundations of metabolism and organ development are being laid, may be uniquely sensitive to arsenic, whereas later prenatal exposure can steer growth in the opposite direction. Because both groups received the same dose, the timing of exposure, not the amount, was the decisive variable, a conclusion with uncomfortable implications for regulatory standards that typically treat a contaminant as a uniform hazard regardless of developmental stage.

The gut microbiome told an equally nuanced story. When the researchers sequenced the 16S ribosomal RNA genes of bacteria in pup feces at three weeks of age, they found that maternal arsenic exposure had elevated gut microbial diversity in the offspring, a counterintuitive result given that reduced diversity is usually framed as a hallmark of a stressed or dysbiotic gut. Arsenic, it appears, does not simply poison the microbial community; it restructures it, opening ecological space for different species. Whether that restructuring is beneficial, harmful, or neutral depends on which microbes move in, and the study’s longer-term experiments suggest the answer differs between the sexes.

To probe those long-term effects, the team extended the experiment beyond weaning. Some pups received only a five-week high-dose arsenic exposure of 10.0 milligrams per liter during adolescence, a level designed to test the impact of a concentrated later-life hit. Others carried the legacy of early-life low-dose exposure from their mothers and then received the same adolescent high dose. Comparing these groups at eight weeks of age revealed that early-life exposure fundamentally changed how the body and its microbes handled the later arsenic assault, and that the changes ran in opposite directions in males and females.

In female pups with the early-life exposure history, the adolescent high dose promoted gut microbial diversity and strengthened the network of interactions among bacterial species, indicating a more interconnected and, in ecological terms, more complex community. At the molecular level, the researchers measured the abundance of arsenic biotransformation genes using a high-throughput quantitative PCR chip that targeted eighty genes involved in arsenic reduction, oxidation, methylation, and transport. In females, genes responsible for reducing arsenate, the pentavalent and generally more toxic form of arsenic, into arsenite were downregulated. Because arsenite is more readily taken up by cells, dampening this reduction pathway coincided with a meaningful outcome: less arsenic accumulated in the females’ kidneys. In other words, the microbial community sculpted by early exposure appeared to blunt the internal dose of the toxin in females, potentially softening the blow of later-life contamination.

Male pups responded in nearly mirror-image fashion. Their gut microbial diversity and network interactions declined under the combined exposure, and instead of retaining arsenic, their bodies excreted more of it in feces, which corresponded with reduced arsenic bioaccumulation in the liver. On the surface, more fecal excretion might sound protective, and for the liver it plausibly was. But the accompanying loss of microbial diversity and the weakening of interaction networks hint at a community under strain, and the study’s authors emphasize that the divergent arsenic metabolic profiles of males and females represent genuinely different biological strategies rather than simply better or worse outcomes. The sex-specific nature of these responses is consistent with a growing body of literature showing that the gut microbiome is shaped by sex hormones and that males and females metabolize xenobiotics differently, but few studies have traced those differences back to exposures occurring before birth.

The technical apparatus behind these conclusions was considerable. The team used inductively coupled plasma mass spectrometry to quantify total arsenic in blood, liver, kidney, and fecal samples, and paired high-performance liquid chromatography with the same detector to separate and measure individual arsenic species, including inorganic arsenate and arsenite and the methylated metabolites monomethylarsonic acid and dimethylarsinic acid. Speciation matters because the toxicity and mobility of arsenic depend entirely on its chemical form, and the gut microbiome is a major site of arsenic methylation and reduction. The researchers also examined histopathology of the ileum and measured the expression of pro-inflammatory cytokines such as IL-8, IL-1 beta, and TNF-alpha, along with transport-related proteins including NaPi-IIb, OATP2B1, and MRP4, which govern how arsenic and its metabolites move across the intestinal barrier. Ecological network analyses of the sequencing data mapped which bacterial groups tended to co-occur or exclude one another, revealing that the architecture of the microbial community, not just its composition, shifted with exposure history and sex.

What emerges from the full dataset is a picture of arsenic as a developmental programming agent whose effects ripple through a biological network spanning metabolism, immunity, and microbial ecology. The authors frame their work as highlighting both the short-term and long-term impacts of arsenic exposure on gut microbiome stability and arsenic metabolic characteristics under different exposure conditions, offering what they call novel insights into the developmental toxicity of early-life exposure. The practical implications are hard to ignore. If the timing of exposure during gestation determines whether offspring grow slower or faster, and if early-life exposure determines whether a later arsenic burden lands in the kidneys or the liver, then risk assessments built on steady-state exposure assumptions may systematically misjudge the hazard, particularly for girls and boys whose responses diverge from the very start.

The study also carries a broader message for microbiome science. The gut microbiome is increasingly recognized as a mediator between environmental chemicals and human health, and this work demonstrates that its mediating role is calibrated by developmental timing and biological sex. For the hundreds of millions of people worldwide whose drinking water exceeds recommended arsenic limits, and for the fetuses and infants exposed in utero and through breast milk, the findings suggest that the microbial consequences of contamination may be set in motion long before symptoms appear, and that protecting the earliest stages of development may be the most effective intervention point. As the researchers and their funders, including the National Natural Science Foundation of China, continue to untangle the mechanisms, the humble gut microbes of laboratory mice have delivered an unmistakable warning: the health effects of arsenic are written differently in males and females, and the writing begins before birth.

Subject of Research: Sex-specific effects of early-life arsenic exposure on body weight, arsenic metabolism, and gut microbiome stability in mice

Article Title: Sex-specific effects of early-life arsenic exposure on body weight, arsenic metabolism, and gut microbiome stability in C57BL/6J mice

Article References: Xiong, S., Jiang, X., Wu, Y., Li, R., Zhao, F., Xiao, P., Yang, Y., Li, Z., Xie, B., Xu, X., Cai, X., Yin, N., & Cui, Y. (2026). Sex-specific effects of early-life arsenic exposure on body weight, arsenic metabolism, and gut microbiome stability in C57BL/6J mice. Microbiome. https://doi.org/10.1186/s40168-026-02535-1

Image Credits: AI Generated

DOI: 10.1186/s40168-026-02535-1

Keywords: arsenic exposure, gut microbiome, developmental toxicity, C57BL/6J mice, sex differences, arsenic metabolism, microbial diversity, prenatal exposure, environmental toxicology, arsenic biotransformation genes, body weight, kidney bioaccumulation

Arsenic is a naturally occurring metalloid found in groundwater, soil, and certain crops across much of the world, and chronic exposure is well established as a risk factor for cardiovascular disease, cancers, and skin lesions. Once absorbed, inorganic arsenic does not simply accumulate unchanged. The body metabolizes it in two successive methylation steps, enzymatically attaching methyl groups to convert inorganic arsenic into monomethylated arsenic, or MMA, and then into dimethylated arsenic, or DMA. These methylated forms are excreted in urine, and for decades the methylation process was considered detoxifying, since the fully dimethylated product is generally less reactive at the cellular level than its predecessors. But this conventional wisdom has been increasingly challenged by studies hinting that trivalent intermediates formed along the pathway may be more toxic than the parent compound itself.

The MANOS research team, led by Margaret Quaid of Boston University School of Public Health together with collaborators at institutions in the United States, El Salvador, and Nicaragua, set out to examine whether specific arsenic metabolism profiles were associated with blood pressure among working men in a region where both arsenic exposure and an unexplained kidney disease overlap. The study included 393 male participants drawn from the broader occupational cohort, and the researchers measured the concentrations of inorganic arsenic, MMA, and DMA in urine samples, expressing each species as a percentage of the total inorganic and methylated arsenic. Blood pressure outcomes included systolic pressure, diastolic pressure, pulse pressure, and mean arterial pressure, all adjusted for age, body mass index, worksite, pesticide use, smoking status, and water consumption.

The results revealed a pattern that at first glance seems counterintuitive. Participants with higher percentages of DMA, the end product of complete arsenic methylation, tended to have higher systolic blood pressure and wider pulse pressure. In the conventional models, each percentage point increase in DMA was associated with a 0.17 millimeter of mercury increase in systolic pressure and a 0.14 millimeter of mercury increase in pulse pressure. Conversely, participants with higher percentages of MMA, indicating incomplete methylation, showed lower systolic and pulse pressures, with each percentage point increase in MMA corresponding to a 0.37 and 0.31 millimeter of mercury decrease respectively. In other words, the men whose bodies pushed arsenic metabolism further along the detoxification pathway were the ones showing elevated cardiovascular readings, not those who stalled at an intermediate step.

Because the three urinary metabolite percentages are mathematically interdependent, the researchers took care to disentangle their individual contributions using two additional analytical strategies. In leave-one-out models, they evaluated the relative effect of two species while statistically holding the third constant. These models reinforced the initial findings: higher DMA at the expense of MMA was associated with increased systolic blood pressure, with an effect estimate of 0.33 millimeters of mercury per percentage point, and increased pulse pressure of 0.29 millimeters of mercury per percentage point. A third approach using principal components analysis, a statistical technique that compresses correlated variables into independent axes representing the two methylation steps, provided converging evidence. The component capturing the second methylation step, the conversion of MMA to DMA, was associated with a 0.93 millimeter of mercury increase in systolic pressure and a 0.74 millimeter of mercury increase in pulse pressure.

The consistency of the effect across three distinct modeling frameworks lends weight to the authors’ conclusion that efficient methylation of inorganic arsenic all the way to DMA is associated with higher blood pressure compared with partial methylation to MMA. This finding complicates the simplistic narrative of methylation as unambiguously protective. It aligns instead with a growing body of research suggesting that the methylation process may generate intermediate trivalent species, such as monomethylarsinous acid, which are highly reactive and can disrupt cellular signaling, endothelial function, and oxidative stress pathways. If the second methylation step is inefficient at clearing these intermediates, or if individuals who methylate rapidly accumulate different arsenic species in tissues, the downstream cardiovascular consequences could differ in ways that conventional toxicity rankings fail to capture.

The biological mechanisms linking arsenic metabolism to blood pressure remain under active investigation, but several plausible pathways have been proposed. Arsenic exposure has been associated with impaired nitric oxide signaling, increased oxidative stress, vascular inflammation, and alterations in arterial stiffness, all of which can elevate systolic pressure and widen pulse pressure, a marker of arterial aging. The methylation process itself consumes methyl groups supplied by S-adenosyl methionine, drawing on one-carbon metabolism, a biochemical network that also regulates homocysteine levels and DNA methylation. Variation in the arsenite methyltransferase gene, known as AS3MT, and in nutritional factors such as folate and B vitamins can shift an individual’s metabolic profile substantially, meaning that two people exposed to identical arsenic levels may carry very different internal arsenic species distributions. The MANOS findings suggest these individual differences are not mere biochemical trivia but may carry meaningful cardiovascular consequences.

The context of the study population adds an important dimension to the findings. MesoAmerican nephropathy, also referred to as chronic kidney disease of unknown etiology, is an epidemic affecting agricultural workers along the Pacific coast of Central America, and arsenic exposure has been proposed among the candidate causes, alongside heat stress, dehydration, and pesticide exposures. By focusing on working men in sugarcane communities in El Salvador and Nicaragua, the MANOS investigators examined arsenic metabolism in a real-world setting of intense occupational and environmental stressors, rather than in a general population survey. The cross-sectional design means the study captures a single moment in time and cannot establish whether arsenic metabolism patterns cause the blood pressure differences or reflect some underlying physiological state. The authors are careful to frame the results as an association, and reverse causation or residual confounding cannot be excluded, particularly in a workforce with high rates of kidney impairment that could alter arsenic excretion.

Nevertheless, the study carries practical implications for how researchers and clinicians think about arsenic risk. Most environmental health surveillance measures total urinary arsenic, treating exposure as a single number. The MANOS results argue that the speciation profile, meaning the relative proportions of inorganic arsenic, MMA, and DMA, conveys additional information about cardiovascular vulnerability that total exposure alone would miss. If future longitudinal studies confirm that the second methylation step is genuinely associated with elevated blood pressure, then arsenic metabolism biomarkers could become part of cardiovascular risk assessment in exposed populations, helping to identify individuals who, despite similar exposure levels, face different health trajectories. Such work would also sharpen the search for modifiable factors, such as nutrition and one-carbon metabolism support, that shape methylation capacity and might therefore mediate arsenic’s cardiovascular effects.

For now, the study stands as a reminder that the body’s handling of a poison can be as consequential as the poison itself. In the cane fields of Central America, where arsenic, kidney disease, and hypertension intersect in an unfolding public health crisis, understanding the chemistry of methylation may prove essential to protecting the hearts and kidneys of the people who live and labor there. The researchers emphasize the importance of arsenic metabolism profiles in cardiovascular risk assessment, and their findings open a clear path for follow-up studies that follow exposed workers over time, track their metabolic profiles, and test whether the blood pressure patterns observed here translate into hypertension, arterial disease, and cardiovascular events in the years ahead.

Subject of Research: The association between arsenic metabolism profiles and blood pressure in MesoAmerican agricultural workers

Article Title: The association of arsenic metabolism and blood pressure: a cross-sectional analysis in the MesoAmerican Nephropathy Occupational Study (MANOS)

Article References: Quaid, M., Rodgers, K., Velázquez, J. J. A., García-Trabanino, R., Jarquin, E., Lopez-Pilarte, D., Leibler, J., Brooks, D., Glabonjat, R. A., Navas-Acien, A., Argos, M., & Scammell, M. K. (2026). The association of arsenic metabolism and blood pressure: a cross-sectional analysis in the MesoAmerican Nephropathy Occupational Study (MANOS). Environmental Health. https://doi.org/10.1186/s12940-026-01333-4

Image Credits: AI Generated

DOI: 10.1186/s12940-026-01333-4

Keywords: arsenic, arsenic metabolism, blood pressure, methylation, MMA, DMA, hypertension, MesoAmerican nephropathy, El Salvador, Nicaragua, environmental health, cardiovascular risk